Jacobs Levy Equity Management Inc. Sells 16,339 Shares of DaVita Inc. (NYSE:DVA)

Jacobs Levy Equity Management Inc. lessened its stake in shares of DaVita Inc. (NYSE:DVA) by 29.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,418 shares of the company’s stock after selling 16,339 shares during the quarter. Jacobs Levy Equity Management Inc.’s holdings in DaVita were worth $6,462,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in DVA. Harvard Management Co. Inc. purchased a new position in DaVita in the second quarter valued at about $55,115,000. FMR LLC grew its position in shares of DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after buying an additional 154,061 shares during the last quarter. Glenmede Trust Co. NA raised its stake in shares of DaVita by 731.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock worth $20,207,000 after acquiring an additional 108,446 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in DaVita during the second quarter valued at approximately $9,615,000. Finally, KBC Group NV boosted its stake in DaVita by 27.3% in the third quarter. KBC Group NV now owns 313,519 shares of the company’s stock valued at $51,395,000 after acquiring an additional 67,250 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Stock Down 1.2 %

Shares of DVA stock opened at $161.39 on Friday. DaVita Inc. has a fifty-two week low of $103.40 and a fifty-two week high of $169.51. The firm has a market capitalization of $13.23 billion, a PE ratio of 17.41, a P/E/G ratio of 0.93 and a beta of 0.90. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. The stock’s 50-day simple moving average is $158.65 and its 200-day simple moving average is $149.93.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. During the same period in the prior year, the business posted $2.85 earnings per share. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. Equities analysts expect that DaVita Inc. will post 9.71 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Javier Rodriguez sold 9,881 shares of DaVita stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $162.85, for a total transaction of $1,609,120.85. Following the completion of the transaction, the chief executive officer now directly owns 887,835 shares in the company, valued at approximately $144,583,929.75. This trade represents a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DVA. Truist Financial upped their price target on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. UBS Group increased their price target on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Finally, Barclays upped their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.